Benztropine
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Benztropine (brand name Cogentin) — Antiparkinson, antidyskinetic; Anticholinergic.
Identification
- Therapeutic class: Antiparkinson, antidyskinetic.
- Pharmacologic class: Anticholinergic.
Pharmacology
- Mechanism of action: Restores dopamine-acetylcholine balance by blocking acetylcholine.
- Onset / peak / duration: Onset within hours; long duration.
- Half-life / therapeutic level: Long; level not routine.
Clinical use
- Indications: Parkinson tremor, drug-induced extrapyramidal symptoms and acute dystonia.
- Usual dose, route, frequency: PO daily; IM or IV for acute dystonia.
- Maximum dose / adjustments: Caution in elderly.
Safety
- Contraindications: Narrow-angle glaucoma, GI or urinary obstruction, myasthenia gravis.
- Black box warning: None.
- Interactions: Other anticholinergics, antihistamines (additive).
- Pregnancy / lactation: Use only if essential.
- High-alert: No.
Adverse effects
- Common side effects: Dry mouth, blurred vision, constipation, urinary retention.
- Serious effects to report: Confusion, hyperthermia, tachycardia, anticholinergic toxicity.
- Antidote / reversal: Physostigmine for severe toxicity.
Nursing process
- Assessment before administration: Glaucoma, urinary and GI status.
- Interventions during therapy: Monitor anticholinergic effects; useful for acute dystonia.
- Monitor: Movement symptoms, anticholinergic effects.
- Evaluation / expected outcome: Reduced tremor or dystonia.
Patient teaching
- Patient teaching: Expect dry mouth; avoid overheating.
- Notify provider if: Confusion, trouble urinating, eye pain.
- Administration tips: IM or IV gives rapid relief of acute dystonia.